Alvogen
Tracked across 9 events · 68 articles · First seen Apr 30, 2026 · Last active Sep 04, 2026
Live sentiment trends, attention charts, and prominence tracking available on the
Ergen Dashboard
Business
Impact: Alvogen is the company presenting at multiple investor conferences, aiming to engage with investors and provide updates on its biosimilar development and commercialization efforts. This event offers a platform for Alvogen to enhance its visibility and potentially attract new investments.
Jun 02, 2026 · 6 articles
Business
Impact: Alvogen resubmitted Biologics License Applications for AVT05 and AVT06 to the United States — Food and Drug Administration>>> (FDA), which is a positive step towards potential market approval and commercialization of its biosimilar products. This action follows extensive work on manufacturing and quality systems.
Jun 04, 2026 · 10 articles
Regulatory
Impact: Alvogen announced that the United States — Food and Drug Administration>>> accepted its Biologics License Application for AVT16, a proposed interchangeable biosimilar to Vedolizumab. This is a significant step for Alvogen>>> in expanding its biosimilar pipeline and market reach.
Jun 08, 2026 · 11 articles
Business
Impact: Alvogen conducted a public offering and concurrent private placement of its ordinary shares, raising approximately $165 million in gross proceeds to fund its operations and development of biosimilar medicines.
Jun 15, 2026 · 6 articles
Business
Impact: Alvogen secured an additional $75 million term loan facility, strengthening its financial position and supporting its growth strategy, including R&D pipeline and product launches. This follows a recent $165 million equity raise, bringing total new capital access to $240 million.
Jul 01, 2026 · 7 articles
Regulatory
Impact: Alvogen is the central entity; the FDA inspection closure and VAI classification remove a key regulatory hurdle, supporting its BLA resubmissions and pipeline advancement.
Jul 29, 2026 · 7 articles
Business
Impact: Alvogen is the licensor and developer, gaining up to $150 million in payments and direct U.S. commercialization rights, enhancing its commercial strategy and potential revenue.
Aug 21, 2026 · 6 articles
Regulatory
Impact: Alvogen is the developer and manufacturer of AVT80; FDA acceptance advances its biosimilar program and could enhance its market prospects.
Aug 31, 2026 · 9 articles
Business
Impact: Alvogen is Dr. Reddy's partner in developing a Keytruda biosimilar, competing in the biosimilar space.
Sep 03, 2026 · 6 articles
ERGEN INTELLIGENCE
Track Alvogen live
Set up alerts, explore relationships, view sentiment trends, and monitor how events impact this entity in real time.
Open Dashboard